Schnyder Crystalline Corneal dystrophy

Overview

Schnyder Crystalline Corneal dystrophy, Schnyder Corneal dystrophy, or Hereditary crystalline dystrophy of Schnyder is a rare disorder characterized by cloudy corneas believed to be due to abnormal lipid deposits in the corneas. A distinctive sign of the condition is the presence of a light-colored ring around the cornea due to abnormal lipid deposit (arcus juvenilis).

Symptoms

  • Decreased visual acuity
  • Arcus juvenilis
  • Cloudy opacification of central cornea
  • Progressively enlarging corneal opacity
  • Increased blood lipids

Causes

SCD is inherited as an autosomal dominant trait with high penetrance and has been mapped to the UBIAD1 gene on chromosome 1p36.3. Although 2/3 of SCD patients also have systemic hypercholesterolemia, the incidence of hypercholesterolemia is also increased in unaffected members of SCD pedigrees. Consequently, SCD is thought to result from a local metabolic defect in the cornea.

Diagnosis

The corneal findings in SCD are very predictable depending on the age of the individual, with initial central corneal haze and/or crystals, subsequent appearance of arcus lipoides in the third decade and formation of midperipheral haze in the late fourth decade. Because only 50% of affected patients have corneal crystals, the International Committee for Classification of Corneal Dystrophies recently changed the original name of this dystrophy from Schnyder crystalline corneal dystrophy to Schnyder corneal dystrophy. Diagnosis of affected individuals without crystalline deposits is often delayed and these individuals are frequently misdiagnosed.

The differential diagnosis of the SCD patient includes other diseases with crystalline deposits such as cystinosis, tyrosinemia, Bietti crystalline dystrophy, hyperuricemia/gout, multiple myeloma, monoclonal gammopathy, infectious crystalline keratopathy, and Dieffenbachia keratitis.

Depositions from drugs such as gold in chrysiasis, chlorpromazine, chloroquine, and clofazamine can also result in corneal deposits and are different from SCD.

Diseases of systemic lipid metabolism that cause corneal opacification, such as lecithin-cholesterol acyltransferase deficiency, fish eye disease and Tangier disease, should also be considered although these are autosomal recessive disorders.

Tests:

  • Confocal microscopy in more advanced stages of SCCD may reveal the absence of corneal nerves.
  • Genetic testing should reveal mutations in the UBIAD1 gene in affected individuals.

Treatment

No local or systemic medical treatment is available to stop the progression of corneal lipid deposition or the alteration of serum cholesterol levels.
 
Penetrating keratoplasty can be performed successfully in those patients with advanced disease, but dystrophy can recur in the graft.
 
Phototherapeutic keratectomy can remove subepithelial crystals if they are causing decreased vision and glare.